As exemplified by the development of CFTR-directed therapies, including approval of Trikafta® in 2019 [119], the majority of recent clinical trials for CF have focused on incorporating these novel small molecule therapeutics into the drug regimen. The gene discussed is CFTR; the disease is cystic fibrosis.